

## Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/Incn19>

### Synthesis of N-Glycosylated Pyridines as New Antiviral Agents

E. S. Ibrahim <sup>a</sup>, G. E.H. Elgemeie <sup>a b e</sup>, M. M. Abbasi <sup>c</sup>, Y. A. Abbas <sup>d</sup>, M. A. Elbadawi <sup>c</sup> & A. M.E. Attia <sup>d</sup>

<sup>a</sup> Chemistry Department, Faculty of Science, Suez Canal University, Egypt

<sup>b</sup> Chemistry Department, Faculty of Science, Cairo University (Bani Suef Branch), Egypt

<sup>c</sup> Chemistry Department, Faculty of Science, Tanta University, Egypt

<sup>d</sup> Chemistry Department, Faculty of Education, Tanta University (Kafr El-Sheikh), Egypt

<sup>e</sup> Chemistry Department, Faculty of Science, Qatar University, P.O.Box 2713, Doha, State of Qatar

Published online: 24 Sep 2006.

To cite this article: E. S. Ibrahim, G. E.H. Elgemeie, M. M. Abbasi, Y. A. Abbas, M. A. Elbadawi & A. M.E. Attia (1995) Synthesis of N-Glycosylated Pyridines as New Antiviral Agents, *Nucleosides and Nucleotides*, 14:6, 1415-1423, DOI: [10.1080/15257779508010701](https://doi.org/10.1080/15257779508010701)

To link to this article: <http://dx.doi.org/10.1080/15257779508010701>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms



## SYNTHESIS OF *N*-GLYCOSYLATED PYRIDINES AS NEW ANTIVIRAL AGENTS

E.S. Ibrahim<sup>a</sup>, G.E.H. Elgemeie<sup>a,†,b</sup>, M.M. Abbasi<sup>c</sup>, Y.A. Abbas<sup>d</sup>, M.A. Elbadawi<sup>c</sup> and A.M.E. Attia<sup>d</sup>.

<sup>a</sup>Chemistry Department, Faculty of Science, Suez Canal University, Egypt

<sup>b</sup>Chemistry Department, Faculty of Science, Cairo University (Bani Suef Branch), Egypt

<sup>c</sup>Chemistry Department, Faculty of Science, Tanta University, Egypt



<sup>d</sup>Chemistry Department, Faculty of Education, Tanta University (Kafr El-Sheikh), Egypt

**Abstract:** A series of 3-cyanopyridine glycosides have been synthesized and evaluated for their inhibitory activity against human immunodeficiency virus (HIV) replication in MT-4 cells. Among the 3-cyanopyridine glycosides 6-(*p*-methylphenyl) and 6-(*p*-aminophenyl) were the most selective inhibitors of HIV replication.

3-Deazauridine and 3-deazacytidine were found to exert marked inhibitory effects on the growth of neoplastic and bacterial culture<sup>1</sup> and also have antiviral activity against RNA viruses<sup>2</sup>. Also 3-deazauridine apparently blocks the action of an enzyme which catalyzes overall amination of UTP to CTP<sup>3</sup>. The 3-deazapyrimidine nucleosides constitute another logical class of analogues with potential biological activity<sup>4,5</sup>. As a part of our program directed for development of new, simple and efficient procedures for the synthesis of antimetabolites<sup>6-11</sup>, we report in this paper a novel synthesis of 3-deazapyrimidine glycosides **5** utilizing our previously reported pyridine-2(1*H*)-ones **3**<sup>12</sup> as starting materials. Compounds **3** can be prepared by the reaction of  $\alpha$ ,  $\beta$ -unsaturated nitriles **1** with acetophenones **2** in boiling ethanol containing ammonium acetate. Compounds **3** reacted with 2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-glucosyl- and galactopyranosyl bromides **4** in the presence of aqueous potassium hydroxide to give the corresponding *N*-glucosides **5a-h** and *N*-galactosides **5i-p**, respectively. The structures of the reaction products **5** were established and confirmed on the basis of their elemental analyses and spectral data (MS, IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR). Thus the analytical data for **5n** revealed a molecular formula C<sub>31</sub>H<sub>30</sub>N<sub>2</sub>O<sub>11</sub> (*m/z* 606). The <sup>1</sup>H NMR spectrum showed a doublet at  $\delta$  6.6 ppm assigned to the anomeric proton of the galactose moiety with a spin-spin

---

<sup>†</sup> Present Address: Chemistry Department, Faculty of Science, Qatar University, P.O.Box 2713, Doha, State of Qatar.



	Ar	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>		Ar	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>
<b>5a</b>	Phenyl	H	OAc	H	<b>6a</b>	Phenyl	H	OH	H
<b>b</b>	Phenyl	CH <sub>3</sub>	OAc	H	<b>b</b>	Phenyl	CH <sub>3</sub>	OH	H
<b>c</b>	Phenyl	OCH <sub>3</sub>	OAc	H	<b>c</b>	Phenyl	OCH <sub>3</sub>	OH	H
<b>d</b>	Phenyl	NH <sub>2</sub>	OAc	H	<b>d</b>	Phenyl	NH <sub>2</sub>	OH	H
<b>e</b>	2-Furyl	H	OAc	H	<b>e</b>	2-Furyl	H	OH	H
<b>f</b>	2-Furyl	CH <sub>3</sub>	OAc	H	<b>f</b>	2-Furyl	CH <sub>3</sub>	OH	H
<b>g</b>	2-Furyl	OCH <sub>3</sub>	OAc	H	<b>g</b>	2-Furyl	OCH <sub>3</sub>	OH	H
<b>h</b>	2-Furyl	NH <sub>2</sub>	OAc	H	<b>h</b>	2-Furyl	NH <sub>2</sub>	OH	H
<b>i</b>	Phenyl	H	H	OAc	<b>i</b>	Phenyl	H	H	OH
<b>j</b>	Phenyl	CH <sub>3</sub>	H	OAc	<b>j</b>	Phenyl	CH <sub>3</sub>	H	OH
<b>k</b>	Phenyl	OCH <sub>3</sub>	H	OAc	<b>k</b>	Phenyl	OCH <sub>3</sub>	H	OH
<b>l</b>	Phenyl	NH <sub>2</sub>	H	OAc	<b>l</b>	Phenyl	NH <sub>2</sub>	H	OH
<b>m</b>	2-Furyl	H	H	OAc	<b>m</b>	2-Furyl	H	H	OH
<b>n</b>	2-Furyl	CH <sub>3</sub>	H	OAc	<b>n</b>	2-Furyl	CH <sub>3</sub>	H	OH
<b>o</b>	2-Furyl	OCH <sub>3</sub>	H	OAc	<b>o</b>	2-Furyl	OCH <sub>3</sub>	H	OH
<b>p</b>	2-Furyl	NH <sub>2</sub>	H	OAc	<b>p</b>	2-Furyl	NH <sub>2</sub>	H	OH

**Table 1:** Comparative potency and selectivity of 3-cyanopyridine-2-one glucosides and galactosides analogues as inhibitors of HIV replication in MT-4 cells.

Compd	EC <sub>50</sub> <sup>a</sup> μM	IC <sub>50</sub> <sup>b</sup> μM	TI <sup>c</sup> (ratio IC <sub>50</sub> /EC <sub>50</sub> )
<b>5a</b>		> 16.5	
<b>5b</b>		> 11.7	
<b>5c</b>		> 15.8	
<b>5d</b>		> 11.6	
<b>5e</b>		> 16.8	
<b>5f</b>		> 8.6	
<b>5g</b>		> 11.6	
<b>5h</b>	11.7	> 11.8	> 1
<b>5j</b>		> 16.5	
<b>5k</b>		> 11.4	
<b>5m</b>		> 11.9	
<b>5n</b>		> 16.4	
<b>5o</b>		> 11.6	
<b>6a</b>		> 21.4	
<b>6f</b>	8.03	> 82.1	> 10.2
<b>6i</b>		> 59.9	
<b>6j</b>	18.6	> 22.3	> 1.2
<b>6k</b>		> 21.5	

- a. Approximate values for 50% effective concentration of MT-4 cells against the cytopathic effect of HIV (EC<sub>50</sub>)
- b. Inhibitor concentration for 50% (IC<sub>50</sub>).
- c. Therapeutic index TI (IC<sub>50</sub>/EC<sub>50</sub>).

coupling constant equal to 8.9 Hz which corresponds to a diaxial orientation for the H-1' and H-2' protons indicating the presence of only β-configuration. The other six protons of the galactopyranosyl ring resonate in the δ 4.12-5.64 ppm region. The remaining four acetoxy groups appeared as four singlets at δ 1.78-2.18 ppm region, while the methyl group of the aglycone resonated at δ 2.41 ppm. The <sup>13</sup>C NMR spectrum of **5n** was characterized by a signal at δ 87.1 ppm corresponding to the C-1' atom of the β-D-galactopyranose. Four signals appeared at δ 170.5-169.4 ppm due to the four acetoxy carbonyl carbon atoms of galactose, while a signal appearing at δ 20.33-20.26 ppm was attributed to the galactose methyl carbons. Another five

**Table 2:** Physical and analytical data for compounds **5a-p** and **6a-p**.

Compd.	MP °C	Yield %	Mol. formula	Found/Calcd. (%)			m/z
				C	H	N	
<b>5a</b>	180	74	$C_{32}H_{30}N_2O_{10}$ (602)	63.9	5.1	4.6	602
				63.8	5.0	4.7	
<b>5b</b>	196	76	$C_{33}H_{32}N_2O_{10}$ (616)	64.6	5.1	4.7	616
				64.3	5.2	4.5	
<b>5c</b>	192	73	$C_{33}H_{32}N_2O_{11}$ (632)	62.9	5.3	4.5	632
				62.7	5.1	4.4	
<b>5d</b>	177	70	$C_{32}H_{31}N_3O_{10}$ (617)	62.5	5.2	6.9	617
				62.2	5.0	6.8	
<b>5e</b>	222	71	$C_{30}H_{28}N_2O_{11}$ (592)	61.0	4.8	4.9	592
				60.8	4.7	4.7	
<b>5f</b>	206	75	$C_{31}H_{30}N_2O_{11}$ (606)	61.5	4.9	4.8	606
				61.4	5.0	4.6	
<b>5g</b>	190	70	$C_{31}H_{30}N_2O_{12}$ (622)	60.0	4.8	4.7	622
				59.8	4.8	4.5	
<b>5h</b>	226	67	$C_{30}H_{29}N_3O_{11}$ (607)	59.4	4.9	7.1	607
				59.3	4.8	6.9	
<b>5i</b>	146	72	$C_{32}H_{30}N_2O_{10}$ (602)	64.0	4.8	4.5	
				63.8	5.0	4.7	
<b>5j</b>	183	74	$C_{33}H_{32}N_2O_{10}$ (616)	64.1	5.2	4.4	616
				64.3	5.2	4.5	
<b>5k</b>	168	71	$C_{33}H_{32}N_2O_{11}$ (632)	62.9	5.2	4.1	632
				62.7	5.1	4.4	
<b>5l</b>	105	68	$C_{32}H_{31}N_3O_{10}$ (617)	62.1	5.1	7.0	
				62.2	5.0	6.8	
<b>5m</b>	180	70	$C_{30}H_{28}N_2O_{11}$ (592)	60.9	4.6	4.5	592
				60.8	4.7	4.7	
<b>5n</b>	220	73	$C_{31}H_{30}N_2O_{11}$ (606)	61.6	5.0	4.6	606
				61.4	5.0	4.6	
<b>5o</b>	210	69	$C_{31}H_{30}N_2O_{12}$ (622)	59.9	4.9	4.6	
				59.8	4.8	4.5	
<b>5p</b>	170	65	$C_{30}H_{29}N_3O_{11}$ (607)	59.6	5.0	6.9	
				59.3	4.8	6.9	
<b>6a</b>	296	83	$C_{24}H_{22}N_2O_6$ (434)	66.6	5.0	6.7	434
				66.4	5.1	6.5	

Table 2. (Continued)

<b>6b</b>	263	85	$C_{23}H_{24}N_2O_6$ (448)	67.2 67.0	5.4 5.4	6.5 6.3	448
<b>6c</b>	256	84	$C_{23}H_{24}N_2O_7$ (464)	64.5 64.7	5.3 5.2	6.3 6.0	464
<b>6d</b>	180	83	$C_{24}H_{23}N_3O_6$ (449)	64.3 64.1	5.1 5.1	9.2 9.4	
<b>6e</b>	295	84	$C_{22}H_{20}N_2O_7$ (424)	62.4 62.3	4.5 4.7	6.8 6.6	424
<b>6f</b>	297	85	$C_{23}H_{22}N_2O_7$ (438)	63.1 63.0	5.0 5.0	6.3 6.4	438
<b>6g</b>	285	81	$C_{23}H_{22}N_2O_8$ (454)	60.6 60.8	4.9 4.8	6.5 6.2	
<b>6h</b>	190	83	$C_{22}H_{21}N_3O_7$ (439)	60.0 60.1	4.8 4.8	9.7 9.6	439
<b>6i</b>	287	84	$C_{24}H_{22}N_2O_6$ (434)	66.5 66.4	5.3 5.1	6.6 6.5	
<b>6j</b>	261	85	$C_{23}H_{24}N_2O_6$ (448)	66.9 67.0	5.4 5.4	6.5 6.3	448
<b>6k</b>	264	82	$C_{23}H_{24}N_2O_7$ (464)	64.6 64.7	5.4 5.2	6.1 6.0	
<b>6l</b>	173	84	$C_{24}H_{23}N_3O_6$ (449)	64.2 64.1	5.3 5.1	9.5 9.4	449
<b>6m</b>	288	83	$C_{22}H_{20}N_2O_7$ (424)	62.5 62.3	4.6 4.7	6.8 6.6	424
<b>6n</b>	285	84	$C_{23}H_{22}N_2O_7$ (438)	63.2 63.0	5.2 5.0	6.6 6.4	438
<b>6o</b>	290	82	$C_{23}H_{22}N_2O_8$ (454)	60.9 60.8	4.9 4.8	6.4 6.2	454
<b>6p</b>	288	84	$C_{22}H_{21}N_3O_7$ (439)	60.3 60.1	5.0 4.8	9.5 9.6	

**Table 3:** Spectral data for selected compounds listed in Table 2.

Compd.	IR(KBr)/cm <sup>-1</sup>	<sup>1</sup> H NMR (DMSO) $\delta$ /ppm
<b>5a</b>	2220 (CN), 1752 (CO ester), 1648 (CO pyridone)	1.82-2.08 (4s, 12H, 4CH <sub>3</sub> CO), 4.21 (m, 2H, H-6',6"), 4.60 (m, 1H, H-5'), 5.32 (m, 2H, H-4' and H-3'), 5.78 (m, 1H, H-2'), 6.80 (d, $J_{1,2}$ = 8.38 Hz, 1H, H-1'), 7.73 (s, 1H, Pyridine H-5), 7.90 (s, 5H, Ar-H), 8.13 (s, 5H, Ar-H).
<b>5b</b>	2222 (CN), 1750 (CO ester), 1636 (CO pyridone)	1.76-2.10 (4s, 12H, 4CH <sub>3</sub> CO), 2.40 (s, 3H, CH <sub>3</sub> ), 4.16 (m, 2H, H-6', 6"), 4.53 (m, 1H, H-5'), 5.21 (m, 2H, H-4' and H-3'), 5.70 (t, 1H, H-2'), 6.76 (d, $J_{1,2}$ = 8.63 Hz, 1H, H-1'), 7.39 (d, 2H, Ar-H), 7.65 (s, 3H, Ar-H), 7.76 (s, 1H, pyridine H-5), 7.96 (s, 2H, Ar-H), 8.30 (d, 2H, Ar-H)
<b>5c</b>	2218 (CN), 1755 (CO ester), 1640 (CO pyridone)	1.85-2.12 (4s, 12H, 4CH <sub>3</sub> CO), 3.90 (s, 3H, OCH <sub>3</sub> ), 4.19 (m, 2H, H-6', 6"), 4.56 (t, 1H, H-5'), 5.18 (m, 2H, H-4' and H-3'), 5.70 (d, 1H, H-2'), 6.65 (d, $J_{1,2}$ = 8.55 Hz, 1H, H-1'), 7.11 (d, 2H, Ar-H), 7.66 (s, 3H, Ar-H), 7.77 (s, 1H, pyridine H-5), 7.95 (s, 2H, Ar-H), 8.30 (d, 2H, Ar-H).
<b>5d</b>	3460, 3380 (NH <sub>2</sub> ), 2220 (CN), 1750(CO ester), 1642(CO pyridone)	1.88-2.09 (4s, 12H, 4CH <sub>3</sub> CO), 4.25 (m, 2H, H-6',6"), 4.60 (m, 1H, H-5'), 5.28 (m, 2H, H-4' and H-3'), 5.80 (t, 1H, H-2'), 6.00 (s, 2H, NH <sub>2</sub> ), 6.70 (d, $J_{1,2}$ = 8.35 Hz, 1H, H-1'), 7.64 (s, 5H, Ar-H), 7.71 (s, 1H, pyridine H-5), 8.23 (d, 4H, Ar-H).
<b>5e</b>	2220 (CN), 1756 (CO ester), 1610 (CO pyridone)	1.67-2.11 (4s, 12H, 4CH <sub>3</sub> CO), 4.12 (d, 2H, H-6',6"), 4.31 (m, 1H, H-5'), 5.32 (m, 2H, H-4' and H-3'), 5.51 (m, 1H, H-2'), 6.38 (d, $J_{1,2}$ = 8.46 Hz, 1H, H-1'), 6.72 (s, 1H, furan H-4), 7.58 (s, 5H, Ar-H), 7.71 (s, 1H, pyridine H-5), 8.03 (s, 1H, furan H-3), 8.18 (s, 1H, furan H-5).
<b>5f</b>	2222 (CN), 1750 (CO ester), 1600 (CO pyridone)	1.64-2.05 (4s, 12H, 4CH <sub>3</sub> CO), 2.46 (s,3H, CH <sub>3</sub> ), 4.08 (m, 2H, H-6',6" and 1H, H-5'), 4.36 (m, 1H, H-4'), 5.34 (m, 2H, H-3' and H-2'), 6.32 (d, $J_{1,2}$ = 8.64 Hz, 1H, H-1'), 6.70 (s, 1H, furan H-4), 7.41 (d, 4H, Ar-H), 7.69 (s, 1H, pyridine H-5), 7.80 (s, 1H, furan H-3), 8.00 (d, 1H, furan H-5).
<b>5g</b>	2218 (CN), 1752 (CO ester), 1610 (CO pyridone)	1.62-2.10 (4s, 12H, 4CH <sub>3</sub> CO), 3.88 (s, 3H, OCH <sub>3</sub> ), 4.05 (m, 2H, H-6',6" and 1H, H-5'), 4.34 (m, 1H, H-4'), 5.30 (t, 1H, H-3'), 5.48 (m, 1H, H-2'), 6.31 (d, $J_{1,2}$ = 8.66 Hz, 1H, H-1'), 6.62 (s, 1H, furan H-4), 7.10 (d, 4H, Ar-H), 7.67 (s, 1H, pyridine H-5), 7.94 (s, 1H, furan H-3), 8.16 (d, 1H, furan H-5)
<b>5h</b>	3460, 3360 (NH <sub>2</sub> ), 2220 (CN), 1760 (CO ester), 1610 (CO pyridone)	1.94-2.16 (4s, 12H, 4CH <sub>3</sub> CO), 4.23 (m, 2H, H-6', 6"), 4.51 (s, 1H, H-5'), 5.22 (m, 2H, H-4' and H-3'), 5.72 (t, 1H, H-2'), 6.00 (s, 2H, NH <sub>2</sub> ), 6.70 (d, $J_{1,2}$ = 8.56 Hz, 1H, H-1'), 6.85 (s, 1H, furan H-4), 7.80 (d, 4H, Ar-H), 7.73 (s, 1H, pyridine H-5), 7.91 (s, 1H, furan H-3), 8.10 (s, 1H, furan H-5).
<b>5i</b>	2220 (CN), 1760 (CO ester), 1650 (CO pyridone)	1.86-2.12 (4s, 12H, 4CH <sub>3</sub> CO), 4.21 (m, 2H, H-6', 6"), 4.63 (m, 1H, H-5'), 5.44 (m, 2H, H-4' and H-3'), 5.60 (t, 1H, H-2'), 6.61 (d, $J_{1,2}$ = 8.38 Hz, 1H, H-1'), 6.90 (s, 1H, furan H-4), 7.65 (s, 5H, Ar-H), 7.78 (s, 1H, pyridine H-5), 8.20 (d, 1H, furan H-3), 8.41 (s, 1H, furan H-5)
<b>5j</b>	2222 (CN), 1758 (CO ester), 1650 (CO pyridone)	1.75-2.15 (4s, 12H, 4CH <sub>3</sub> CO), 2.40 (s, 3H, CH <sub>3</sub> ), 4.15 (m, 2H, H-6',6" and 1H, H-5'), 4.65 (t, 1H, H-4'), 5.57 (m, 2H, H-3' and H-2'), 6.65 (d, $J_{1,2}$ = 8.71 Hz, 1H, H-1'), 6.85 (s, 1H, furan H-4), 7.35 (d, 4H, Ar-H), 7.75 (d, 1H, furan H-3), 8.10 (s, 1H, pyridine H-5), 8.34 (d, 1H, furan H-5).
<b>5m</b>	2218 (CN), 1754 (CO ester), 1650 (CO pyridone)	1.86-2.16 (4s, 12H, 4CH <sub>3</sub> CO), 4.22 (m, 2H, H-6',6"), 4.64 (m, 1H, H-5'), 5.41 (m, 2H, H-4' and H-3'), 5.60 (t, 1H, H-2'), 6.58 (d, $J_{1,2}$ = 8.68 Hz, 1H, H-1'), 6.88 (s, 1H, furan H-4), 7.65 (s, 5H, Ar-H), 7.76 (s, 1H, pyridine H-5), 8.20 (d, 1H, furan H-3), 8.34 (s, 1H, furan H-5).



Table 3: (Continued)

<b>5a</b>	2220 (CN), 1760 (CO ester), 1650 (CO pyridone)	1.78-2.18 (4s, 12H, 4CH <sub>3</sub> CO), 2.41 (s, 3H, CH <sub>3</sub> ), 4.12 (m, 2H, H-6', 6" and 1H, H-5'), 4.65 (t, 1H, H-4'), 5.51 (m, 2H, H-3' and H-2'), 6.60 (d, J <sub>1,2</sub> = 8.90 Hz, 1H, H-1') 6.85 9s, 1H, furan H-4), 7.32 (d, 4H, Ar-H), 7.78 (s, 1H, pyridine H-5), 8.10 (d, 1H, furan H-3), 8.33 (d, 1H, furan H-5).
<b>6c</b>	3600-3150 (OH), 2220 (CN), 1630 (CO pyridone)	3.25-3.78 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 3.88 (s, 3H, OCH <sub>3</sub> ), 4.67 (t, 1H, 2'-OH), 5.18 (d, 1H, 3'-OH), 5.24 (s, 1H, 4'-OH), 5.50 (d, 1H, 6'-OH), 6.20 (d, J <sub>1,2</sub> = 8.64 Hz, 1H, H-1'), 7.12 (d, 2H, Ar-H), 7.63 (m, 3H, Ar-H), 7.74 (m, 2H, Ar-H), 7.81 (s, 1H, pyridine H-5), 8.25 (d, 2H, Ar-H)
<b>6d</b>	3650-3200 (OH), 2222 (CN), 1635 (CO pyridone)	3.21-3.74 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.65 (t, 1H, 2'-OH), 5.15 (d, 1H, 3'-OH), 5.21 (s, 1H, 4'-OH), 4.45 (d, 1H, 6'-OH), 5.88 (s, 2H, NH <sub>2</sub> ), 6.18 (d, J <sub>1,2</sub> = 8.55 Hz, 1H, H-1'), 6.68 (d, 2H, Ar-H), 7.56 (m, 3H, Ar-H), 7.62 (s, 1H, pyridine H-5), 7.72 (m, 2H, Ar-H), 8.00 (d, 2H, Ar-H).
<b>6e</b>	3600-3180 (OH) 2218 (CN) 1610 (CO Pyridone)	3.18-3.65 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.61 (t, 1H, 2'-OH), 5.18 (d, 2H, 3'-OH and 4'-OH), 5.46 (s, 1H, 6'-OH), 6.14 (d, J <sub>1,2</sub> = 8.63 Hz, 1H, H-1'), 6.85 (dd, 1H, furan H-4), 7.54 (t, 3H, Ar-H), 7.72 (d, 1H, furan H-3), 8.08 (s, 1H, pyridine H-5), 8.11 (d, 2H, Ar-H), 8.24 (dd, 1H, furan H-5).
<b>6f</b>	3650-3150 (OH) 2220 (CN), 1610 (CO pyridone)	2.32 (s, 3H, CH <sub>3</sub> ), 3.26-3.85 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.65 (t, 1H, 2'-OH), 5.15 (d, 2H, 3'-OH and 4'-OH), 5.45 (s, 1H, 6'-OH), 6.15 (d, J <sub>1,2</sub> = 8.52 Hz, 1H, H-1'), 6.85 (m, 1H, furan H-4), 7.35 (d, 4H, Ar-H), 7.71 (d, 1H, furan H-3), 8.05 (s, 1H, pyridine H-5), 8.15 (d, 1H, furan H-5).
<b>6g</b>	3600-3200 (OH) 2222 (CN), 1600 (CO pyridone)	3.21-3.77 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 3.86 (s, 3H, OCH <sub>3</sub> ), 4.65 (s, 1H, 2'-OH), 5.20 (s, 2H, 3'-OH and 4'-OH), 5.54 s, 1H, 6'-OH), 6.18 (d, J <sub>1,2</sub> = 8.38 Hz, 1H, H-1'), 6.88 (dd, 1H, furan H-4), 7.18 (d, 2H, Ar-H), 7.65 (d, 1H, furan H-3), 8.00 (s, 1H, pyridine H-5), 8.13 (m, 1H, furan H-5), 8.21 (d, 2H, Ar-H).
<b>6j</b>	3640-3180 (OH), 2220 (CN), 1630 (CO pyridone)	2.28 (s, 3H, CH <sub>3</sub> ), 3.21-3.78 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.63 (t, 1H, 2'-OH), 5.16 (d, 1H, 3'-OH), 5.21 (s, 1H, 4'-OH), 5.42 (d, 1H, 6'-OH), 6.18 (d, J <sub>1,2</sub> = 9.30 Hz, 1H, H-1'), 7.38 (d, 2H, Ar-H), 7.60 (m, 3H, Ar-H), 7.78 (m, 2H, Ar-H), 7.84 (s, 1H, pyridine H-5), 8.18 (d, 2H, Ar-H).
<b>6k</b>	3660-3200 (OH), 2220 (CN), 1620 (CO pyridone)	3.31-3.78 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 3.86 (s, 3H, OCH <sub>3</sub> ), 4.61 (t, 1H, 2'-OH), 5.18 (d, 1H, 3'-OH), 5.25 (s, 1H, 4'-OH), 5.50 (d, 1H, 6'-OH), 6.20 (d, J <sub>1,2</sub> = 8.58 Hz, 1H, H-1'), 7.11 (d, 2H, Ar-H), 7.60 (m, 3H, Ar-H), 7.70 (s, 1H, pyridine H-5), 7.81 (d, 2H, Ar-H), 8.05 (d, 2H, Ar-H).
<b>6l</b>	3650-3180 (OH, NH <sub>2</sub> ), 2220 (CN), 1620 (CO pyridone)	3.28-3.87 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.65 (t, 1H, 2'-OH), 5.12 (d, 1H, 3'-OH), 5.24 (s, 1H, 4'-OH), 5.48 (d, 1H, 6'-OH), 5.96 (s, 2H, NH <sub>2</sub> ), 6.21 (d, J <sub>1,2</sub> = 8.66 Hz, 1H, H-1'), 6.68 (d, 2H, Ar-H), 7.58 (m, 3H, Ar-H), 7.68 (s, 1H, pyridine H-5) 7.85 (m, 2H, Ar-H), 8.05 (d, 2H, Ar-H).
<b>6a</b>	3660-3200 (OH), 2222 (CN), 1625 (CO pyridone)	2.40 (s, 3H, CH <sub>3</sub> ), 3.18-3.66 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.62 (t, 1H, 2'-OH), 5.18 (d, 2H, 3'-OH and 4'-OH), 5.45 (s, 1H, 6'-OH), 6.15 (d, J <sub>1,2</sub> = 8.48 Hz, 1H, H-1'), 6.88 (m, 1H, furan H-4), 7.40 (d, 4H, Ar-H), 7.69 (d, 1H, furan H-3), 8.05 (s, 1H, pyridine H-5), 8.15 (d, 1H, furan H-5).
<b>6p</b>	3600-3200 (OH, NH <sub>2</sub> ), 2220 (CN), 1600 (CO pyridone)	3.22-3.68 (m, 6H, H-6', 6", H-5', H-4', H-3' and H-2'), 4.58 (t, 1H, 2'-OH), 5.08 (d, 1H, 3'-OH), 5.17 (s, 1H, 4'-OH), 5.49 (d, 1H, 6'-OH), 5.90 (s, 2H, NH <sub>2</sub> ), 6.16 (d, J <sub>1,2</sub> = 8.55 Hz, 1H, H-1'), 6.74 (d, 2H, Ar-H), 6.88 (dd, 1H, furan H-4), 7.60 (d, 1H, furan H-3), 7.78 (s, 1H, pyridine H-5), 8.00 (d, 2H, Ar-H), 8.14 (d, 1H, furan H-5).

signals at  $\delta$  61.7, 67.7, 67.9, 70.3 and 71.3 ppm were assigned to C-6', C-4', C-2', C-3' and C-5', respectively. On the other hand, the signal of the carbonyl carbon atom of aglycone appeared at  $\delta$  162.7 ppm and the nitrile carbon atom appeared at  $\delta$  115.1 ppm. The preparation of crystalline 1-( $\beta$ -D-glycopyranosyl)3-cyanopyridine-2-ones **6a-p** was achieved by removing the blocking acetyl groups on treatment with methanolic ammonia at 0°C. The structures of compounds **6** were established on the basis of elemental analyses and spectral data. Thus, the analytical data for **6f** revealed a molecular formula  $C_{23}H_{22}N_2O_7$  ( $m/z$  438). The  $^1\text{H}$ NMR spectra showed the anomeric proton as a doublet at  $\delta$  6.18 ppm ( $J_{1,2} = 9.3$  Hz) indicating the presence of only the  $\beta$ -configuration. The other six glucose protons appeared as a multiplet at  $\delta$  3.21-3.78 ppm, while the four hydroxy groups of the glucose moiety resonated at  $\delta$  4.63-5.48 ppm (exchangeable by  $D_2O$ ). The  $^{13}\text{C}$  NMR spectra was characterized by a signal at  $\delta$  96.8 ppm corresponding to the C-1' atom of  $\beta$ -D-glucopyranose. Another five signals at  $\delta$  60.6, 69.7, 72.9, 77.1 and 78.2 ppm were assigned to C-6', C-4', C-2', C-3' and C-5' of the glucose moiety, respectively. In summary, we have achieved a regiospecific synthesis of interesting 3-deazapyrimidine nucleosides by the reaction of pyridine-2(1*H*)-ones with  $\alpha$ -halomonosugars. These nucleosides can be utilized as an excellent starting materials for the synthesis of other carbohydrate derivatives.

#### Antiviral Activity:

The anti-HIV activity and cytotoxicity of some 3-cyano-4 and 6-disubstituted-2-pyridone glucosides and galactosides are shown in Table 1. Among these types of glycosides the 4-furyl-6(p-methylphenyl) glucoside **6f** turned out to be the most selective anti-HIV agent, followed by 4-phenyl-6(p-methylphenyl) galactosides **6j** and 4-furyl-6 (p-aminophenyl) glucose tetraacetate **5h**., while; 4-furyl-6-phenyl- and 4, 6-diphenyl-, 4-furyl-6 (p-methylphenyl)-, and 4-phenyl-6(p-methylphenyl) glucosides or galactosides were devoid any therapeutic index at the indicated concentration.

#### EXPERIMENTAL:

##### 1-(2,3,4,6-Tetra-*O*-acetyl- $\beta$ -D-glucopyranosyl)-3-cyanopyridine-2-ones; **5**

##### General Coupling Procedure:

To a solution of 2(1*H*)-pyridineones **3a-h** (0.01 mol) in aqueous potassium hydroxide (0.56 g, 0.01 mol, in 6 mL of distilled water) was added a solution of 2,3,4,6-tetra-*O*-acetyl- $\alpha$ -D-glucopyranosyl bromide **4** (4.521 g, 0.011 mol) in acetone (30 mL). The reaction mixture was stirred at room temperature until judged complete by TLC (8-12h), then evaporated under reduced pressure at 40°C and the residue washed with distilled water to remove the formed potassium bromide. The product was dried and crystallized from ethanol to afford colourless crystals (cf. Table 2).

##### 1-( $\beta$ -D-Glucopyranosyl)-3-cyanopyridine-2-ones; **6**

##### General Procedure for Nucleoside Deacylation:

Dry gaseous ammonia was passed through a solution of protected nucleosides **5** (0.5 gm) in dry methanol (20 mL) at 0°C for about 0.5 hour. The reaction mixture was then stirred at 0°C until judged complete by

TLC (20-24 h). The mixture was evaporated under reduced pressure at 40°C giving a solid residue which was crystallized from methanol to afford colourless crystals (cf. Table 2).

### Biological Procedure

The compounds **5a-p** and **6a-p** were dissolved in dimethyl sulfoxide then diluted 1:100 in cell culture medium before preparing serial half-Log<sub>10</sub> dilutions. T<sub>4</sub> Lymphocytes were added and after a brief interval HIV-1 is added, resulting in 1:200 final dilution of the compound. Uninfected cells with the compound serve as a toxicity control, and infected and uninfected cells without the compound serve as basic controls. Cultures are incubated at 37° in a 5% carbon dioxide atmosphere for 6 days. The tetrazolium salt, XTT, is added to all wells, and cultures are incubated to allow formazan color development by viable cells. Individual wells are analyzed spectrophotometrically to quantitate formazan production, and in addition are viewed microscopically for detection of viable cells and confirmation of protective activity. Drug-treated virus-infected cells are compared with drug-treated noninfected cells and with other appropriate controls on the same plate. Data are reviewed in comparison with other tests done at the same time and a determination about activity is made.

### Acknowledgements

The authors are greatly indebted to Dr. John P. Bader, Dr. V. L. Narayanan and Dr. Michael R. Boyd, AIDS Department and Drug Synthesis & Chemistry Branch of Health and Human Services, National Institutes of Health for their valuable in vitro anti-HIV activity and antitumor activities of our samples.

### REFERENCES

1. M.J. Robins, B.L. Currie, R.K. Robins and A. Bloch, *Proc. Am. Assoc. Cancer Res.*, **1969**, *10*, 73.
2. W.M. Shannon, G. Arnett, and F.M. Schabel, Jr., *Antimicrob. Agents Chemother.*, **1972**, *2*, 159.
3. M.J. Robins and A.S.K. Lee, *J. Med. Chem.*, **1975**, *18*, 1070.
4. A. Bloch, G. Dutschman, B. Currie, R.K. Robins and M.J. Robins, *J. Med. Chem.*, **1973**, *16*, 294.
5. R.R. Copp and V.E. Marquez, *J. Med. Chem.*, **1991**, *34*, 208.
6. G.E.H. Elgemeie, N.M. Fathy, L.M. Faddah and M.Y. Ebeid, *Arch. Pharm. (Weinheim)*, **1991**, *324*, 149.
7. G.E.H. Elgemeie, A.M. Elzanate and A.K. Mansour, *J. Chem. Soc. Perkin Trans. 1*, **1992**, 1073.
8. G.E.H. Elgemeie, H.A. Regaila and N. Shehata, *J. Chem. Soc. Perkin Trans. 1*, **1990**, 1267.
9. G.E.H. Elgemeie, A.M. Elzanate and A.K. Mansour, *Bull. Chem. Soc. Jpn.*, **1993**, *66*, 555.
10. G.E.H. Elgemeie and B.A. Hussain, *Tetrahedron*, **1994**, *50*, 199.
11. G.E.H. Elgemeie, A.M.E. Attia, D.S. Farag and S.M. Sherif, *J. Chem. Soc., Perkin Trans. 1*, **1994**, 3.
12. G.E.H. Elgemeie, H.A. Regaila and N. Shehata, *Sulfur Lett.*, **1989**, *9*, 253.

Received August 3, 1994

Accepted February 17, 1995